RxDoctor Payments Data

Richard Pish, MD

Internal Medicine · Uniontown, PANPI 1124021605

Payments from drug & device makers

$30,001in general payments, 2019–2025

Across 1,229 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$10K
  • Novo Nordisk$2K
  • GSK$2K
  • Johnson & Johnson$2K
  • Pfizer$1K
  • AbbVie$1K
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$20,567100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis35$9,934
Novo Nordisk151$2,478
GSK118$1,652
Johnson & Johnson91$1,603
Pfizer101$1,450
AbbVie(2 entities)125$1,368
AstraZeneca71$1,336
Lilly USA, LLC82$1,215
Boehringer Ingelheim72$1,032
Boston Scientific15$821
Amgen(2 entities)42$728
Sanofi-aventis U.S. LLC39$620
Bayer27$493
E.r. Squibb & Sons, L.L.C.29$475
Amarin Pharma, Inc.22$385
Abbott18$374
Exact Sciences15$332
Esperion Therapeutics, Inc.14$328
Vanda Pharmaceuticals Inc.11$268
Merck12$198
Biohaven Pharmaceutical Holding Company Ltd.10$195
Astellas Pharma US Inc10$174
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$159
Kowa Pharmaceuticals America, Inc.10$157
Otsuka America Pharmaceutical, Inc.9$155
Idorsia Pharmaceuticals US Inc8$152
Radius Health, Inc.2$137
Akcea Therapeutics, Inc.8$127
Intuitive Surgical1$125
Takeda Pharmaceuticals U.S.A., Inc.7$118
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$116
GRT US Holding, Inc.1$115
Genentech USA, Inc.6$114
Phathom Pharmaceuticals, Inc.5$108
Biofire Diagnostics, LLC1$105
Daiichi Sankyo Inc.5$104
Dexcom, Inc.5$69
Sunovion Pharmaceuticals Inc.5$66
Teva Pharmaceuticals USA, Inc.5$63
Biohaven Pharmaceuticals, Inc.3$46
Avanir Pharmaceuticals, Inc.3$45
Eisai Inc.2$45
Insulet Corporation2$41
Regeneron Healthcare Solutions, Inc.1$38
Xeris Pharmaceuticals, Inc.2$38
Sanofi1$28
Amneal Pharmaceuticals LLC1$26
Madrigal Pharmaceuticals1$24
UCB, Inc.1$20
Corcept Therapeutics1$20
Harmony Biosciences LLC1$20
Axsome Therapeutics, Inc.1$18
Currax Pharmaceuticals LLC1$16
Sun Pharmaceutical Industries Inc.1$16
Grifols USA, LLC1$15
ARS Pharmaceuticals Operations, Inc.1$15
Ultragenyx Pharmaceutical Inc.1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15
Tactile Systems Technology Inc1$14
Alfasigma USA, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,001 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$238,618
Medicare patients
479
Services billed
4,942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$100,319
XareltoRivaroxaban64$36,375
MounjaroTirzepatide34$34,666
ProliaDenosumab17$28,675
RybelsusSemaglutide12$27,058
MyrbetriqMirabegron57$21,265
FarxigaDapagliflozin Propanediol37$18,672
JardianceEmpagliflozin17$17,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,749
TradjentaLinagliptin15$13,248
Mirabegron ErMirabegron27$11,661
Spiriva RespimatTiotropium Bromide21$11,021
EntrestoSacubitril/Valsartan15$8,358
Jentadueto XrLinagliptin/Metformin Hcl27$6,570
InvokanaCanagliflozin11$6,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,450$100,319170 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto Xr$1,032$48,41280 claims
Johnson & JohnsonXarelto, Invokana$1,603$42,63975 claims
Lilly USA, LLCMounjaro$1,215$34,66634 claims
AmgenProlia$728$28,67517 claims
Novo NordiskRybelsus$2,478$27,05812 claims
Astellas Pharma US IncMyrbetriq$174$21,26557 claims
GSKTrelegy Ellipta, Incruse Ellipta$1,652$18,94634 claims
AstraZenecaFarxiga$1,336$18,67237 claims
NovartisEntresto$9,934$8,35815 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$1,505176 claims
AbbVieSynthroid$1,368$1,36632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Uniontown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →